Provided by Tiger Trade Technology Pte. Ltd.

Plus Therapeutics, Inc.

0.2599
+0.026011.12%
Post-market: 0.2500-0.0099-3.81%19:59 EST
Volume:8.49M
Turnover:2.06M
Market Cap:46.36M
PE:-0.57
High:0.2599
Open:0.2300
Low:0.2223
Close:0.2339
52wk High:2.31
52wk Low:0.1634
Shares:178.37M
Float Shares:178.37M
Volume Ratio:0.89
T/O Rate:4.76%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4560
EPS(LYR):-1.9544
ROE:-522.50%
ROA:-65.58%
PB:9.17
PE(LYR):-0.13

Loading ...

Company Profile

Company Name:
Plus Therapeutics, Inc.
Exchange:
NASDAQ
Establishment Date:
1996
Employees:
21
Office Location:
2710 Reed Road,Suite 160,Houston,Texas,United States
Zip Code:
77051
Fax:
210 974 6901
Introduction:
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186Re obisbemeda, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.

Directors

Name
Position
Marc H. Hedrick
President, Chief Executive Officer and Director
Richard J. Hawkins
Chairman of the Board
An van Es Johansson
Director
Howard Clowes
Director
Kyle Guse Esq
Director
Robert Lenk
Director

Shareholders

Name
Position
Marc H. Hedrick
President, Chief Executive Officer and Director
Andrew Sims
Chief Financial Officer